3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.

Iveson, Timothy J; Kerr, Rachel S; Saunders, Mark P; Cassidy, Jim; Hollander, Niels Henrik; Tabernero, Josep; Haydon, Andrew; Glimelius, Bengt; Harkin, Andrea; Allan, Karen; +26 more... McQueen, John; Scudder, Claire; Boyd, Kathleen Anne; Briggs, Andrew; Waterston, Ashita; Medley, Louise; Wilson, Charles; Ellis, Richard; Essapen, Sharadah; Dhadda, Amandeep S; Harrison, Mark; Falk, Stephen; Raouf, Sherif; Rees, Charlotte; Olesen, Rene K; Propper, David; Bridgewater, John; Azzabi, Ashraf; Farrugia, David; Webb, Andrew; Cunningham, David; Hickish, Tamas; Weaver, Andrew; Gollins, Simon; Wasan, Harpreet S; Paul, James; (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. LANCET ONCOLOGY, 19 (4). pp. 562-578. ISSN 1470-2045 DOI: https://doi.org/10.1016/S1470-2045(18)30093-7

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S1470-2045(18)30093-7

Abstract

Share

Download

Filename: 1-s2.0-S1470204518300937-main.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar